



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/295,463	04/13/1999	LEX M. COWSERT	ISIS-3455	7206
35807	7590	10/12/2006	EXAMINER	
Isis Pharmaceuticals, Inc. 1896 Rutherford Road Carlsbad, CA 92008			MORAN, MARJORIE A	
			ART UNIT	PAPER NUMBER
			1631	

DATE MAILED: 10/12/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER
----------

ART UNIT
----------

PAPER
-------

20060609

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

After the date of mailing of the Examiner's Answer, the current examiner was made aware that the IDS filed 10/10/06 had not been considered at any time during prosecution. The examiner apologizes for the oversight. The IDS filed 10/10/06 has been considered in full and an initialed, signed and dated copy of the Form 1449 is included herewith.

In addition, the examiner inadvertently omitted a heading for Appendix 11, directed to Related Proceedings, in the Examiner's Answer mailed 6/14/06. Again, the examiner apologizes for the error, and includes a new copy of the Examiner's Answer to the Appeal Brief filed 2/14/06 which includes a heading for appendix 11.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marjorie A. Moran whose telephone number is (571) 272-0720. The examiner can normally be reached on Monday-Friday; 6 am-2:30 pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (571) 272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

*Marjorie A. Moran*  
10/12/06

Marjorie A. Moran  
Primary Examiner  
Art Unit: 1631



UNITED STATES PATENT AND TRADEMARK OFFICE

---

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

Application Number: 09/295,463  
Filing Date: April 13, 1999  
Appellant(s): COWSERT ET AL.

**MAILED**  
**OCT 12 2006**  
**GROUP 1600**

---

Paul K. Legaard  
For Appellant

**EXAMINER'S ANSWER**

This is in response to the appeal brief filed 2/14/06 appealing from the Office action  
mailed 5/23/05.

**(1) Real Party in Interest**

A statement identifying by name the real party in interest is contained in the brief.

**(2) Related Appeals and Interferences**

The examiner is not aware of any related appeals, interferences, or judicial proceedings which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

**(3) Status of Claims**

The statement of the status of claims contained in the brief is correct.

**(4) Status of Amendments After Final**

No amendment after final has been filed.

**(5) Summary of Claimed Subject Matter**

The summary of claimed subject matter contained in the brief is correct.

**(6) Grounds of Rejection to be Reviewed on Appeal**

The appellant's statement of the grounds of rejection to be reviewed on appeal is correct.

**(7) Claims Appendix**

The copy of the appealed claims contained in the Appendix to the brief is correct.

**(8) Evidence Relied Upon**

5,463,564	AGRAFIOTIS et al.	10-1995
5,639,603	DOWER et al.	6-1997
5,720,923	HAFF et al.	2-1998

5,650,122                      HARRIS et al.                      7-1997

UHLMANN et al. "Antisense oligonucleotides: A new therapeutic principle." Chemical Reviews, vol. 90, no. 4 (June 1990), pages 543-584.

**(9) Grounds of Rejection**

The following ground(s) of rejection are applicable to the appealed claims:

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 55, 56, 58-72, 74-76, 78-83, 85-87, and 99-102 are again rejected, as previously set forth in the office action of 6/9/04 and further elucidated in the Advisory Action of 12/9/04, under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a NEW MATTER rejection.

The amendment filed 8/4/03 introduces new matter as follows. Amended claim 55 now recites generating virtual compounds according to thermodynamic property "and at least one criteria selected from...". This limitation wherein said generating is practiced via the combination of a thermodynamic property "and" the listed properties to control the generating step in claim 55 has not been found as filed regarding written basis. Figures 4-6 fail to provide support for the combination of a thermodynamic

property and at least one other criterion in a step of generating in silico compounds. As the Figures disclose that a step of generating oligonucleotide sequences is performed BEFORE any step of calculating thermodynamic properties or scores, there is no support in the Figures for generating an in silico compound of any kind "according to" a thermodynamic property, whether in combination with another a property or alone. The method disclosed in the Figures is one wherein a list of PREVIOUSLY GENERATED compounds is selected based on various properties. This is not reflected in the steps of the rejected claims. Further, and as previously set forth, the assessment of a compound for a criterion such as hybridization (targeting) is performed separately from the thermodynamic property calculations. Figures 5 and 6 present these steps as being separate, with no overlapping or connecting elements which would lead one skilled in the art to interpret them as being performed in combination, as embodied by the limitations of the pending claims. Pages 19-24 of the originally filed specification also fail to provide support for the limitations in question. Page 19, lines 16-18 discloses that FOLLOWING calculation of thermodynamic properties, desired sequence properties to be scored are selected. The disclosure of pages 19-24 contains references to the Figures. Again, it is noted that all "scoring" is preformed as a selection step AFTER generation of virtual oligonucleotides, and is not performed as part of the generation step itself. Further, the criteria listed in the claims for combination with thermodynamic properties do not coincide with the "sequence properties" or "homology" calculations disclosed by the specification and Figures as being scored following the thermodynamic calculations. The above noted NEW MATTER is also present in independent claims

56, 58-60, 62-67, 69-72, 74, 75, 78-82, 85-87, 99-102, as well as claims dependent directly or indirectly from these independent claims via their dependence.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 55, 56, 58-72, 74-76, 78-83, 85-87, and 99-102 are again rejected under 35 U.S.C. 103(a) as being unpatentable over AGRAFIOTIS et al. (5,463,564) in view of UHLMANN et al. (1990), DOWER et al. (5,639,603), and HAFF et al. (5,720,923) or HARRIS et al. (5,650,122).

The claims are directed to methods of generating or evaluating in silico compounds according to a thermodynamic property and at least one other criterion, and robotically assaying synthetic compounds for one or more desired physical, chemical, or biological properties. Some methods also include a step of synthesizing at least some of the virtual compounds before assaying. Claims 58, 60-672, 74-83, 85-87, and 100-102 limit the compounds to nucleobases or oligonucleotides.

AGRAFIOTIS generically describes computerized design of a directed diversity chemical library, as well as computer-directed synthesis and testing of designed compounds for desired properties (abstract and Figure 2). AGRAFIOTIS specifically

Art Unit: 1631

teaches that his design, synthesis, and testing are iterative steps, and teaches testing and evaluation for desired chemical, biological and/or physical properties (col. 3, lines 27- 68). AGRAFIOTIS teaches that his chemical library thus designed may comprise a variety of different compounds, including drugs and bioactive compounds (col. 5, lines 46-55), and teaches that it is well-known in the art for such libraries to comprise oligonucleotides as bioactive compounds (col. 2, lines 32-44). AGRAFIOTIS teaches design/evaluation of his virtual compounds according to various criteria, including binding to a target (col. 16, line 60-col. 17, line 25), but does not specifically teach design/evaluation according to the properties recited in the instant claims.

UHLMANN generally teaches methods of design and synthesis of a variety of drugs, specifically antisense oligonucleotides. Pages 553-556 describe design of antisense molecules according to thermodynamic and "other criteria" in order to achieve desired properties. Pages 561-562 teach synthesizing and testing for desired properties, specifically hybridization/melting temperature (i.e. a thermodynamic property) and ability to bind to a target. Pages 565-567 disclose other desired properties, including stability and bioavailability. UHLMANN does not teach computer-controlled PCR or ELISA.

DOWER teaches automated synthesis and testing of oligonucleotides with desired properties, specifically those with desired hybridization and receptor binding properties (col's 16-19).

HAFF teaches automated PCR.

HARRIS teaches automated ELISA.



It would have been obvious to one of ordinary skill in the art at the time of invention to have used the method of automated design and synthesis of drugs, as taught by AGRAFIOTIS, to design and synthesize the antisense drugs according to the thermodynamic and binding parameters taught by UHLMANN, combined with the synthesis steps taught by DOWER, where the motivation would have been to facilitate design and testing of new drugs by rational drug design, as taught by UHLMANN as being desired by those of skill in the art (p. 544). It would further have been obvious to have assayed the antisense drugs in the method of AGRAFIOTIS, UHLMANN and DOWER using either the automated PCR or ELISA of HAFF or HARRIS, respectively, where the motivation would have been to "scale up" the volume of product, as taught by HAFF (col. 2, lines 20-63), and/or to increase the reliability of results, as taught by HARRIS (col. 2, lines 35-58). One of skill in the art would reasonably have expected success in designing, synthesizing and testing the antisense oligonucleotide drugs of UHLMANN using the combined in silico design and computer-implemented steps of AGRAFIOTIS, in combination with the computer-implemented assays of HAFF or HARRIS, because both AGRAFIOTIS and DOWER teach that computer-implemented design and synthesis of oligonucleotides from combinatorial libraries is known in the art to have been successful.

#### **(10) Response to Argument**

Art Unit: 1631

A) In response to the argument that the method of AGRAFIOTIS **begins** with a synthesis step followed by a "generation of a virtual library" and thus does not teach generation or evaluation of in silico or virtual compounds **prior to** synthesis or assay, it is noted that appellants have, by their own arguments, admitted that AGRAFIOTIS teaches BOTH in generation of a virtual (or in silico) library and synthesis of compounds. Appellants argument that these steps are not aught in the exact order of the claims are not persuasive for the following reasons. First, AGRAFIOTIS does teach a design step **prior to** a synthesis and/or assay step where he teaches that his method is reiterative and that steps of computer-controlled evaluation and design (computer-generation of models/compounds) are followed by synthesis of the designed compounds (col. 3, line 35-col. 4, line 25). In addition, AGRAFIOTIS explicitly teaches a "synthesis protocol generator" which incorporates "desired activity properties" BEFORE "robotics synthesis instructions" occur in Figure 2. Second, the instant claims recite open claim language, and thus do not exclude additional steps such as those also taught by AGRAFIOTIS.

In response to the argument that the design (in silico generation or evaluation) step of AGRAFIOTIS is not carried out "according to" thermodynamic and other criteria, it is noted that the "synthesis protocol generator" of AGRAFIOTIS uses structural, electronic, and physiochemical criteria, and **receptor fit criteria** to generate a directed diversity chemical library (col. 16, lines 42-68), thus AGRAFIOTIS does, in fact, teach using a variety of criteria to generate/evaluate his computer-designed compounds, wherein at least one criterion is "targeting to a functional region." It is noted that the

Art Unit: 1631

rejection is made over a combination of references, wherein UHLMANN and DOWER teach design and evaluation of nucleic acids according to thermodynamic (e.g. melting temperature) and targeting to a functional region of a target nucleic acid (e.g. hybridization/binding properties) criteria. Appellant merely argues that the combination of references does not overcome the “deficiencies” argued for the AGRAFIOTIS reference, and does not set forth any specific arguments with regard to the combination of references.

In response to the argument that the “synthesis protocol generator” of AGRAFIOTIS only directs synthesis of actual compounds, but not in silico compounds, it is noted that col. 17, lines 6-25 and col. 18, lines 15-40 of AGRAFIOTIS describe construction of structure-activity models and identification of compounds by the synthesis protocol generator from those models TO BE synthesized in the next iteration. Clearly, compounds must be generated in silico in order for filtering and selection of compounds for FUTURE synthesis to occur.

B) In response to the argument that Figures 4 and 5 provide support for “numerous criteria” which can be used to generate in silico compounds, it is noted that Figure 4 does teach a step (304) of generating all possible oligonucleotides capable of hybridizing to a target sequence, which in combination with step (305) of generating virtual oligonucleotides, may be interpreted as providing support for a step of generating virtual compounds according to a criterion of “targeting to a ...target nucleic acid” as recited in the claims, but this “generation” step is clearly NOT performed “according to”

Art Unit: 1631

a thermodynamic property. Figure 4 does not disclose any step of *generation* or according to a thermodynamic property, but discloses only a step (306) of *calculating* thermodynamic properties AFTER the generation step. A step of calculating a thermodynamic property may be interpreted to be a step of evaluating according to that property, but then the step of “generating” by hybridization is clearly not one of “evaluating.” Step of listing (348) and selecting (349, in Figure 5) are separate steps following the generation and calculation steps and are not interpreted to be either generation or evaluation steps. Neither Figure 4 nor Figure 5 discloses ANY step which includes generating or evaluating an oligonucleotide or any other compound according to BOTH thermodynamic AND another criterion.

In response to the argument that there is “confusion” between “generating in silico virtual *compounds*” as recited in claim 55, and “generating oligonucleotide sequences,” it is noted that Figures 4 and 5, and page 16 of the specification, to which appellants point to support, specifically disclose generating “oligonucleotide sequences.” While the instant specification does provide support for generating “synthetic compounds” on page 1, the overall disclosure is directed to design and synthesis of oligonucleotide sequences, thus appellant’s attempt to distinguish the “compounds” of claim 55 from “oligonucleotides” is confusing. Further, claims 58, 60, 62-72, 74-76, 78-83, 85-87, 100-102 specifically recite generating/evaluating nucleobase or oligonucleotides, therefore the argument is moot with regard to these claims.

Art Unit: 1631

**(11) Related Proceeding(s) Appendix**

No decision rendered by a court or the Board is identified by the examiner in the Related Appeals and Interferences section of this examiner's answer.

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,

Marjorie A. Moran

Primary Examiner

Art Unit 1631

*Marjorie A. Moran*  
10/12/06

Conferees:

*Ardin Marschel* 10/2/06  
Ardin Marschel, SPE

*Peter Paras, Jr.*  
Peter Paras, Jr., SPE